Chai Discovery is a privately held company tracked for investment-relevant business and technology developments.
This slot renders the company's funding history: dates, rounds, amounts, valuations and lead investors once populated in data/funding-rounds.json.
Chai Discovery's Chai 2 model reaches 15% success rate in de novo antibody design versus 0.1% state-of-the-art, enabling zero-shot molecule generation with sufficient hits for statistical property optimization and hill-climbing.